FibroBiologics Common Financials
| FBLG Stock | 4.23 0.09 2.17% |
The financial analysis of FibroBiologics Common is a critical element in measuring its lifeblood. Investors should not minimize FibroBiologics Common's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
FibroBiologics |
Understanding current and past FibroBiologics Common Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of FibroBiologics Common's financial statements are interrelated, with each one affecting the others. For example, an increase in FibroBiologics Common's assets may result in an increase in income on the income statement.
The data published in FibroBiologics Common's official financial statements typically reflect FibroBiologics Common's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving FibroBiologics Common's quantitative information. For example, before you start analyzing numbers published by FibroBiologics accountants, it's essential to understand FibroBiologics Common's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Please note, the presentation of FibroBiologics Common's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, FibroBiologics Common's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of FibroBiologics Common's management manipulating its earnings.
FibroBiologics Common Stock Summary
FibroBiologics Common competes with Equillium, Kineta, DiaMedica Therapeutics, Valneva SE, and Vivani Medical. FibroBiologics Common is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 31573L105 |
| Location | Texas; U.S.A |
| Business Address | 455 East Medical |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.fibrobiologics.com |
| Phone | 281 651 5150 |
FibroBiologics Common Key Financial Ratios
There are many critical financial ratios that FibroBiologics Common's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that FibroBiologics Common reports annually and quarterly.| Net Income | (16.48 M) | ||||
| Total Asset | 11.82 M | ||||
| Retained Earnings | (24.36 M) |
FibroBiologics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining FibroBiologics Common's current stock value. Our valuation model uses many indicators to compare FibroBiologics Common value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across FibroBiologics Common competition to find correlations between indicators driving FibroBiologics Common's intrinsic value. More Info.FibroBiologics Common Stock is one of the top stocks in net income category among its peers. It also is rated as one of the top companies in total debt category among its peers . At this time, FibroBiologics Common's Net Loss is most likely to decrease significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value FibroBiologics Common by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.FibroBiologics Common Systematic Risk
FibroBiologics Common's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. FibroBiologics Common volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on FibroBiologics Common correlated with the market. If Beta is less than 0 FibroBiologics Common generally moves in the opposite direction as compared to the market. If FibroBiologics Common Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one FibroBiologics Common is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of FibroBiologics Common is generally in the same direction as the market. If Beta > 1 FibroBiologics Common moves generally in the same direction as, but more than the movement of the benchmark.
FibroBiologics Common July 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of FibroBiologics Common help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of FibroBiologics Common Stock. We use our internally-developed statistical techniques to arrive at the intrinsic value of FibroBiologics Common Stock based on widely used predictive technical indicators. In general, we focus on analyzing FibroBiologics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build FibroBiologics Common's daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 73.72 | |||
| Value At Risk | (15.91) | |||
| Potential Upside | 10.35 |
Complementary Tools for FibroBiologics Stock analysis
When running FibroBiologics Common's price analysis, check to measure FibroBiologics Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroBiologics Common is operating at the current time. Most of FibroBiologics Common's value examination focuses on studying past and present price action to predict the probability of FibroBiologics Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroBiologics Common's price. Additionally, you may evaluate how the addition of FibroBiologics Common to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |